Dioxaphetyl butyrate

Dioxaphetyl butyrate (INN; trade names Amidalgon, Spasmoxal) is an opioid analgesic which is a diphenylacetic acid derivative, related to other open-chain opioid drugs such as dextropropoxyphene, levacetylmethadol (LAAM), lefetamine and dimenoxadol.[1][2]

Dioxaphetyl butyrate

Clinical data
Other names	Amidalgon, Spasmoxal
Routes of administration	Oral, Other ROA Unknown
ATC code	none
Legal status
Legal status	AU: S9 (Prohibited) CA: Schedule I DE: Anlage I (Authorized scientific use only) US: Schedule I
Identifiers
IUPAC name Ethyl 4-morpholin-4-yl-2,2-di(phenyl)butanoate
CAS Number	467-86-7 Y
PubChem CID	48194
ChemSpider	43838 N
UNII	G751H98FY4
CompTox Dashboard (EPA)	DTXSID20196914
ECHA InfoCard	100.006.731
Chemical and physical data
Formula	C22H27NO3
Molar mass	353.45 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1
InChI InChI=1S/C22H27NO3/c1-2-26-21(24)22(19-9-5-3-6-10-19,20-11-7-4-8-12-20)13-14-23-15-17-25-18-16-23/h3-12H,2,13-18H2,1H3 N Key:LQGIXNQCOXNCRP-UHFFFAOYSA-N N
NY (what is this?)  (verify)

It produces similar effects to other opioids, including dependence, euphoria, analgesia, sedation, constipation, dizziness and nausea.[3]

In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregate manufacturing quota of zero.[4]